Kissei Pharmaceutical announced that GlaxoSmithKline has discontinued the development of the novel agent for diabetes, remogliflozin (KGT-1681). It was as a result of evaluating circumstances including the development status of SGLT2 inhibitors by competitors.
Kissei has discovered the SGLT2 inhibitor, remogliflozin and the SGLT1 inhibitor, KGA-3235 for diabetes, and licensed the development and marketing right of the agents in the US and Europe to GlaxoSmithKline.
Remogliflozin is in the stage of phase-II clinical studies, whereas KGA-3235 is in the stage of phase-I clinical study.
With regard to the development of SGLT inhibitors, GlaxoSmithKline has decided to continue to develop KGA-3235.